RADAR-CNS (Remote assessment of disease and relapse - Central Nervous System), a major new research programme supported by the Innovative Medicines Initiative (IMI) started in April 2016 and will develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology.
This programme aims to improve patients' quality of life, and potentially to change how these and other chronic disorders are treated.
Continuous remote assessment using smartphones and wearable devices provides a complete picture of a patient’s condition at a level of detail which was previously unachievable. Moreover, it could potentially allow treatment to begin before a patient’s health deteriorates, preventing the patient relapsing or becoming more ill before they seek treatment.
In recent years, the quality and quantity of data that we can collect using wearable devices and smartphones has exploded. It may be that this sort of data can improve clinical care simply by providing more accurate information. - Prof Matthew Hotopf, Director of NIHR Maudsley Biomedical Research Centre in London
To continue reading, click here.